CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.6200
+0.0400 (+1.12%)
As of 3:58PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.5800
Open3.5800
Bid3.6000 x 2200
Ask3.6100 x 800
Day's Range3.5000 - 3.7100
52 Week Range1.8500 - 6.1600
Volume797,352
Avg. Volume2,898,179
Market Cap372.331M
Beta (3Y Monthly)2.95
PE Ratio (TTM)N/A
EPS (TTM)-0.2820
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Trade prices are not sourced from all markets
  • Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi
    Zacks11 days ago

    Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

    Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.

  • Reuters12 days ago

    UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug

    Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug. The lawsuit alleges that the approval of Ruzurgi, a rival drug from privately held Jacobus Pharmaceutical Co, in May violated provisions of FDA regulations and Catalyst's rights to exclusivity for its drug, Firdapse. For years, patients were able to access the same drug for free from Jacobus, a small, family-run company in New Jersey, through an FDA program called "compassionate use".

  • Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?
    Zacks12 days ago

    Catalyst (CPRX) Up 14.1% Since Last Earnings Report: Can It Continue?

    Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire12 days ago

    Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration (FDA) and several related parties challenging the recent approval of a new drug application and related drug labeling for Jacobus Pharmaceutical Company’s drug Ruzurgi™ for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in pediatric patients. The complaint was filed today in the United States District Court for the Southern District of Florida.

  • GlobeNewswire20 days ago

    Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the Company will be presenting at the Jefferies 2019 Global Healthcare Conference, in New York. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Thursday, June 6 at 10:30 am ET.

  • Penny Stocks to Buy Using Technical Analysis for June 2019
    Investopedia25 days ago

    Penny Stocks to Buy Using Technical Analysis for June 2019

    Traders should look for short-term opportunities in penny stocks as macroeconomic events cast a shadow of uncertainty on the markets.

  • GlobeNewswire25 days ago

    Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has amended its license agreement for Firdapse® to expand its commercial territory. The original license was for North America, and has been amended to include Japan.  Upon the achievement of a certain milestone in Japan, Catalyst will have the option to expand the territory further to include most of Asia and Central and South America. “We are pleased to have expanded the scope of our license to include Japan and possibly other territories, as we believe that Japan represents an attractive strategic opportunity for Catalyst,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals, Inc. “The available treatment options for LEMS patients in Japan are very limited and without an approved evidence-based therapy.

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of CPRX earnings conference call or presentation 13-May-19 12:30pm GMT

    Q1 2019 Catalyst Pharmaceuticals Inc Earnings Call

  • Catalyst Pharmaceuticals settles patent dispute with Northwestern University
    American City Business Journals27 days ago

    Catalyst Pharmaceuticals settles patent dispute with Northwestern University

    Catalyst Pharmaceuticals has ended a legal fight with Northwestern University, according to a recent filing with the U.S. Securities and Exchange Commission. The settlement resolves a patent dispute in which neither company admitted fault, according to Catalyst. The dispute arose from a Aug. 27, 2009, license agreement in which Catalyst tapped Northwestern to develop CPP-115, a drug intended to treat infantile spasms.

  • Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse
    Zackslast month

    Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse

    Catalyst Pharma (CPRX) gains on the successful launch of Firdapse. The company is looking to develop drug for additional indications.

  • ETF Trendslast month

    5 Biotech Stocks to Watch in the Second Half of 2019

    Biotechnology stocks can generate strong opportunities, as they are riddled with catalytic events through the development, regulatory and commercial processes. Catalyst Pharmaceuticals  CPRX [NSC] – $3.14  has had an incredibly strong start to the year. After receiving FDA approval for Firdapse back in November of 2018 for adults with Lambert-Eaton Myasthenic Syndrome (LEMS), Catalyst has pleased investors with its commercialization efforts and the potential revenue that the treatment would generate.

  • Are These 2 Beaten-Down Biotech Stocks Worth the Risk?
    Motley Foollast month

    Are These 2 Beaten-Down Biotech Stocks Worth the Risk?

    Catalyst Pharmaceuticals and Novavax have had tough go of it in May. Could better days be close at hand?

  • Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
    Zackslast month

    Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

    Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.

  • Implied Volatility Surging for Catalyst Pharmaceuticals (CPRX) Stock Options
    Zackslast month

    Implied Volatility Surging for Catalyst Pharmaceuticals (CPRX) Stock Options

    Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.

  • Catalyst Pharmaceuticals Posts Strong Q1 Sales for Firdapse
    Motley Foollast month

    Catalyst Pharmaceuticals Posts Strong Q1 Sales for Firdapse

    But serious questions remain about potential competition from a newly approved rival drug.

  • Why Catalyst Pharmaceuticals Briefly Spiked Today
    Motley Foollast month

    Why Catalyst Pharmaceuticals Briefly Spiked Today

    Catalyst posted outstanding first-quarter numbers this morning, but the good times may not last.

  • Catalyst Pharmaceuticals Inc (CPRX) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Catalyst Pharmaceuticals Inc (CPRX) Q1 2019 Earnings Call Transcript

    CPRX earnings call for the period ending March 31, 2019.

  • Catalyst Pharmaceutical (CPRX) Reports Q1 Loss, Tops Revenue Estimates
    Zackslast month

    Catalyst Pharmaceutical (CPRX) Reports Q1 Loss, Tops Revenue Estimates

    Catalyst (CPRX) delivered earnings and revenue surprises of 92.31% and 1045.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Catalyst: 1Q Earnings Snapshot

    On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update

    -Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed.

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...

  • Why Catalyst Pharmaceuticals Stock Is Jumping Today
    Motley Foollast month

    Why Catalyst Pharmaceuticals Stock Is Jumping Today

    The drugmaker is rebounding after a big plunge earlier this week that might have been a little overdone.

  • Here’s Why Analysts Remain Confident on Catalyst (CPRX) Stock
    SmarterAnalystlast month

    Here’s Why Analysts Remain Confident on Catalyst (CPRX) Stock

    This week turned out to be a nightmare for shareholders of Catalyst Pharmaceuticals (CPRX), as the stock price plummeted over 50%. So what caused investors to hit the exits? The key concern is competition.On Tuesday, privately held and New Jersey-based Jacobus Pharmaceuticals secured FDA approval for its Lambert-Eaton myasthenic syndrome (LEMS) drug, Ruzurgi, for patients between six to 17 years of age. LEMS is a rare and progressive neuromuscular disease caused by problems in neuromuscular transmission. Investors see this approval as a very big problem for Catalyst as its lead drug, Firdapse, also contains the same active ingredient to treat LEMS. However, analysts remain largely positive in the long run."We believe that Jacobus’ approval [...] is largely a symbolic FDA gesture addressing the political pressures surrounding drug pricing. Although the long-time brushfire competition between Catalyst (Firdapse) and Jacobus (Ruzurgi) ended up in both scoring a regulatory nod, we think the race was effectively over when Firdapse passed the finish line first and ended up with the big prize. Ruzurgi’s approval, in our view, has minimal impact on Firdapse for the following reasons: (1) Firdapse and Ruzurgi are approved in non-overlapping adult and pediatric LEMS patient population, respectively; (2) compared to the adult LEMS patient population, pediatric LEMS patient numbers could be insignificant," said H.C. Wainwright's Andrew Fein.Echoing H.C. Wainwright's sentiment, Oppenheimer analyst Leland Gershell says his initial impression is that of an over-reaction to the downside that may be driven more by fear than by fact. Gershell noted, "We expect to hear Firdapse's launch continuing on the strong trajectory described on the company's 4Q18 call held March 19, which will likely include sales as well as other metrics e.g. patient starts."Last but not the least, Cantor's Charles Duncan commented, "We do not see this approval having a large impact in Firdapse’s market potential as we guesstimate that the pediatric population consists of <5% of the prevalent LEMS population. Therefore, we do not believe it is a slippery slope for Catalyst and Firdapse, as the company has already gained traction with a prescriber and patient base, despite only one quarter into its post-approval launch. In our view, the clinical development (two P3 trials), expanded access, and patient assistance program underscores Firdapse leadership in the LEMS community. This creates goodwill that should benefit the brand and the company in its efforts to identify additional LEMS patients, and in its future label expansion efforts (CMS, Musk-MG). Also, we see the two labels as clearly distinguished and therefore, should there be efforts to capture adult market share made for Ruzurgi, then the label would be violated, in our view."These analysts are not the only fans of the biotech company on Wall Street, as TipRanks analytics exhibit CPRX stock as a Strong Buy. Based on 6 analysts polled in the last 3 months, all 6 rate the stock a Buy.Many biotech companies are making their way towards the cannabis medical sector as a source of inspiration to find the benefits of cannabis plant use for patients with various diseases. To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target * Cannabis Stock Village Farms (VFF) Has a Lot Going for It

  • Why Catalyst Pharmaceuticals Is Getting Crushed Today
    Motley Fool2 months ago

    Why Catalyst Pharmaceuticals Is Getting Crushed Today

    Catalyst's shares are in free fall today after the FDA's surprise approval of a rival LEMS medication.